Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • Investor news
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Press releases
    • In the news
    • Investor news
    • Videos
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • Investor news
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Press releases
    • In the news
    • Investor news
    • Videos
    • News archive

Posts in: press release

3Q26 report
press releaseinvestor
eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET TodayNovember 19, 2026
3Q26 investor call on Nov 19
press releaseinvestor
eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026November 12, 2026
Fireside chat with Water Tower Research - tomorrow at 11AM EST
heltzenpress releaseinvestor
CEO to discuss commercialization, key milestones, and potential catalysts in fireside chat with WTROctober 21, 2026
Q2 2026 investor update
heltzenpress releaseinvestor
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET todayAugust 20, 2026
NCT process advances beyond original commercial-scale economic targets
press releaseinvestorscienceperrimanNCT
eXoZymes' NCT process achieves 10-fold productivity increase, advancing beyond original commercial-scale economic targetsAugust 18, 2026
EXOZ to host Q2 2026 investor update on Aug 20 @ 5PM Eastern
press releaseinvestor
EXOZ to host Q2 2026 investor update on Aug 20 @ 5PM EasternAugust 11, 2026
EXOZ and LBNL awarded Genesis Mission grant from DOE
heltzenpress releasescience
eXoZymes selected for DoE’s Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturingJuly 23, 2026
EXOZ gets $2 Million NIH Grant to Advance Cannabinoids for Drug Discovery
heltzenpress releaseinvestormedicinesciencecannabinoidskorman
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug DiscoveryJune 24, 2026
$6M fundraise closed
press releaseinvestor
eXoZymes Inc. Announces Closing of $6 Million Public OfferingJune 17, 2026
EXOZ announces pricing of public offering
press releaseinvestor
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and WarrantsJune 8, 2026
Previous page
Page 1 of 6
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark